Navigation Links
Techne Corporation Announces That Dr. Roeland Nusse Has Accepted a Seat on Its Board of Directors
Date:5/26/2010

MINNEAPOLIS, May 26 /PRNewswire-FirstCall/ -- Techne Corporation (Nasdaq: TECH) today announced that Roeland Nusse, Ph.D. has accepted a position on the Techne Corporation Board of Directors and will also serve as a member of Techne's Nominations and Governance Committee.  Dr. Nusse's initial term will begin immediately and run through October 28, 2010.  Techne Corporation's shareholders reelect all Directors on an annual basis.

Dr. Nusse has been a professor or associate professor in the Department of Developmental Biology at Stanford University and an investigator at the Howard Hughes Medical Institute since 1990. He has also been the chair of the Department of Developmental Biology at Stanford since 2007.  His studies involve the activity of proteins that determine cell fate during embryogenesis. His lab has also used purified proteins to manipulate the behavior of stem cells in culture, in particular neural stem cells.

Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The Netherlands) as a staff scientist and ultimately head of the Department of Molecular Biology. Dr. Nusse earned a bachelor's degree in biology in 1975 from the University of Amsterdam and a doctorate in molecular biology from the Netherlands Cancer Institute in 1980. He did his postdoctoral fellowship at the University of California, San Francisco.

Dr. Nusse was elected to the prestigious National Academy of Sciences, a private organization of scientists and engineers dedicated to the furtherance of science and its use for the general welfare, at the Academy's 147th annual meeting in April 2010.  Dr. Nusse was previously named a member of the European Molecular Biology Organization in 1988, a member of the Royal Dutch Academy of Sciences in 1997 and a member of the American Academy of Arts and Sciences in 2001.

Mr. Thomas E. Oland, Techne Corporation's Chairman and CEO, said, "I am extremely pleased that Dr. Nusse has accepted a position on our Board of Directors.  Dr. Nusse is an esteemed scientist and his background and experience will be invaluable during the Board's strategic discussions.  He will also serve as another strong mentor for the Company's senior scientific staff. We are very fortunate to have a person of his caliber on our Board.  I am very confident that he will make a significant contribution to our future success."

Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.


'/>"/>
SOURCE Techne Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010
2. Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009
3. Techne Corporation Declares Dividend
4. TechNet Urges Swift U.S. Senate Approval of FCC Nominees Julius Genachowski and Robert McDowell
5. Techne Corporation Board Member Recognized
6. Techne Corporation Announces the Retirement of G. Arthur Herbert, a Member of Its Board of Directors
7. Techne Corporation Announces That John L. Higgins has Accepted a Seat on Technes Board
8. Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009
9. Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program
10. Techne Corporation Declares Dividend
11. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... ... demand that it has found among its diverse customer base. The latest entry ... in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of performing routine electrochemical biosensing has increased dramatically. Primarily driven by the ... and quantification of various analytes in complex samples. , Screen-printed ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... Safety, HealthCare, and Finance sectors announced today that Leaders in Community ... and deploy a community-based supportive services program to reduce recidivism in ... expanding its presence in the state. ... This new program, which is expected to commence ...
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
Breaking Biology News(10 mins):